A Study to comparison of fingolimod and dimethyl fumarate in patients with multiple sclerosis in real world

Trial Profile

A Study to comparison of fingolimod and dimethyl fumarate in patients with multiple sclerosis in real world

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Apr 2017 Results (n=789) comparing data for fingolimod versus dimethyl fumarate, through addition of natalizumab as the third arm, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 20 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top